Jeito Capital, a leading global private equity fund dedicated to biopharma, has significantly bolstered its leadership team with two strategic appointments. The firm announced that Elaine Caughey has joined as Partner, Business Development and Investor Relations, while Sarah Shackelton has been named Partner, Talent. These hires bring decades of high-level experience from top-tier investment funds and biopharma companies, reinforcing Jeito's commitment to accelerating portfolio development.
Strengthening Strategic Leadership
The appointments of Caughey and Shackelton are highly synergistic, combining complementary skills that span the entire drug development value chain. Their collective expertise in life sciences operations, investment strategy, and executive recruitment directly supports Jeito’s model of providing hands-on guidance to its portfolio companies. This strategic enhancement is designed to advance breakthrough therapies for patients by building robust and well-led organizations.
These additions build on a series of recent high-profile hires, including senior advisors from Novartis, Bristol Myers Squibb, and Johnson & Johnson. This pattern underscores Jeito's strategy of assembling a collective of seasoned executives to guide its investments. The firm aims to build the next generation of leading global biopharma companies by integrating deep industry knowledge at every level.
Driving Business Development and Investor Relations
Elaine Caughey will leverage over 30 years of experience to help portfolio companies enhance their strategic value through partnerships and acquisitions. Her background includes serving as Deputy Chief Operating Officer at Blackstone Life Sciences and Chief Business Officer at Kymera Therapeutics. She also held significant business development and market access roles at Biogen, where she was involved in several major drug launches.
Caughey's deep understanding of the investment ecosystem will be instrumental in strengthening relationships with investors for both Jeito's funds and its portfolio companies. She is also tasked with contributing to the expansion of Jeito’s operations in the United States. Caughey expressed her enthusiasm for joining Jeito during a new phase of its development, aiming to help its companies reach their full potential.
Cultivating Top-Tier Talent
Sarah Shackelton brings over two decades of experience in building high-caliber leadership teams and boards for innovative, venture-backed companies. In her role as Partner, Talent, she will work closely with the investment team on leadership due diligence and executive hiring. Her previous positions as Chief Talent Officer at Oxford Science Enterprises and Partner at Abingworth underscore her expertise in this critical area.
Shackelton emphasized that talent is a powerful driver of company value when treated as a genuine strategic input. At Jeito, she will partner with portfolio CEOs and board members to address the people-related challenges that arise as companies scale. Her focus will be on building the outstanding leadership required to drive Jeito’s clinical programs and portfolio companies forward.
A Vision for Accelerated Growth
Dr. Rafaèle Tordjman, Founder and CEO of Jeito Capital, welcomed the new partners, highlighting how their expertise strengthens the firm's unique collective model. She noted that their extensive experience in the biopharma and investment sectors aligns perfectly with Jeito's mission. Their appointments are seen as crucial to accelerating therapeutic innovation and supporting the scale-up of portfolio companies.
The strategic appointments of Elaine Caughey and Sarah Shackelton mark a significant step in Jeito Capital's evolution. By integrating top-tier expertise in business development and talent management, the firm reinforces its hands-on, value-add investment philosophy. This move not only enhances support for its current portfolio but also positions Jeito to continue building market-leading biopharma companies dedicated to addressing unmet patient needs.